Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Nausea × nabiximols × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Marijuana Abuse 3 Pain 2 Neoplasms 2 Recurrence 1 Parasomnias 1 Pancreatic Neoplasms 1 Nausea 1 Glioblastoma 1 Chronic Pain 1 Cachexia 1 Brain Neoplasms 1 Anxiety Disorders 1 Anorexia 1 Advanced Malignant Solid Tumor 1

Interventions

Aprepitant 11 Palonosetron 8 Dexamethasone 7 Ondansetron 5 Olanzapine 5 netupitant 2 Fluorouracil 2 Calcium Dobesilate 2 yangzheng xiaoji 1 rolapitant 1 ramosetron 1 niraparib 1 netupitant, palosentron drug combination 1 nabiximols 1 isatuximab 1 ginger extract 1 fosaprepitant 1 dolasetron 1 casopitant 1 Tropisetron 1 Therapeutics 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 Oxaliplatin 1 Octreotide 1 Midazolam 1 Leucovorin 1 Lactose 1 L 758298 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡